<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="letter"><?properties open_access?><!-- Original-type: sc--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">15870719</article-id><article-id pub-id-type="pmc">2361767</article-id><article-id pub-id-type="pii">6602569</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6602569</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Studies</subject></subj-group></article-categories><title-group><article-title>A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Veronese</surname><given-names>M L</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>W</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Giantonio</surname><given-names>B</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Berlin</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Shults</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Davis</surname><given-names>L</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Haller</surname><given-names>D G</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>O'Dwyer</surname><given-names>P J</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA 19104, USA</aff><author-notes><corresp id="caf1"><label>*</label>Author for correspondence: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:peter.odwyer@uphs.upenn.edu">peter.odwyer@uphs.upenn.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>03</day><month>05</month><year>2005</year></pub-date><pub-date pub-type="collection"><day>17</day><month>05</month><year>2005</year></pub-date><pub-date pub-type="ppub"><day>23</day><month>05</month><year>2005</year></pub-date><volume>92</volume><issue>10</issue><fpage>1846</fpage><lpage>1849</lpage><history><date date-type="received"><day>16</day><month>09</month><year>2004</year></date><date date-type="rev-recd"><day>10</day><month>03</month><year>2005</year></date><date date-type="accepted"><day>11</day><month>03</month><year>2005</year></date></history><copyright-statement>Copyright 2005, Cancer Research UK</copyright-statement><copyright-year>2005</copyright-year><permissions><copyright-holder>Cancer Research UK</copyright-holder></permissions><abstract><p>Inhibition of epidermal growth factor receptor (EGFR) signalling contributes to the therapy of colorectal cancer. Gefitinib, an oral EGFR tyrosine kinase inhibitor, shows supra-additive growth inhibition with irinotecan and fluoropyrimidines in xenograft models. We designed a study to determine the tolerability and efficacy of gefitinib in combination with irinotecan, infusional 5-fluorouracil (5-FU) and leucovorin (LV), on a 2-week schedule. Among 13 patients with advanced colorectal cancer, 10 required dose reductions of irinotecan and 5-FU because of dehydration, diarrhoea, and neutropenia, seven of whom required hospitalisation, three with neutropenic fever. One patient achieved partial response and seven had disease stabilisation. The combination of this standard chemotherapy regimen with gefitinib is associated with excessive toxicity, suggesting an interaction at a pharmacokinetic or pharmacodynamic level.</p></abstract><kwd-group><kwd>colon cancer</kwd><kwd>gefitinib</kwd><kwd>EGFR</kwd><kwd>irinotecan</kwd></kwd-group></article-meta></front><body><p>The addition of irinotecan to 5-fluorouracil (5-FU) results in response rates (RR) of 30&#x02013;40&#x00025;, and improved survival to about 14&#x02013;16 months in metastatic colorectal cancer (<xref ref-type="other" rid="bib5">Douillard <italic>et al</italic>, 2000</xref>; <xref ref-type="other" rid="bib26">Saltz <italic>et al</italic>, 2000</xref>). Weekly and every 3-week schedules of irinotecan demonstrate comparable toxicity and efficacy (<xref ref-type="other" rid="bib24">Rougier <italic>et al</italic>, 1997</xref>; <xref ref-type="other" rid="bib7">Fusch <italic>et al</italic>, 2003</xref>), but the weekly combination of irinotecan/5-FU shows excessive toxicity (<xref ref-type="other" rid="bib23">Rothenberg <italic>et al</italic>, 2001</xref>). The FOLFIRI regimen (<xref ref-type="other" rid="bib5">Douillard <italic>et al</italic>, 2000</xref>) is less toxic, and infusional 5-FU or capecitabine combinations are favoured (<xref ref-type="other" rid="bib10">Han <italic>et al</italic>, 2003</xref>; <xref ref-type="other" rid="bib28">Tewes <italic>et al</italic>, 2003</xref>; <xref ref-type="other" rid="bib1">Bajetta <italic>et al</italic>, 2004</xref>; <xref ref-type="other" rid="bib13">Jordan <italic>et al</italic>, 2004</xref>).</p><p>Expression of the epidermal growth factor receptor (EGFR) has been associated with outcome in colon cancer (<xref ref-type="other" rid="bib17">Mayer <italic>et al</italic>, 1993</xref>; <xref ref-type="other" rid="bib25">Saloman <italic>et al</italic>, 1995</xref>). Gefitinib is an oral EGFR tyrosine kinase inhibitor with an excellent safety profile. The combination of gefitinib and irinotecan has shown supra-additive growth inhibition in colorectal cancer cell lines and in xenograft models (<xref ref-type="other" rid="bib15">Koizumi <italic>et al</italic>, 2004</xref>). In a human head and neck cancer cell line treated with gefitinib before or during 5&#x02032;-deoxy-5-fluorouridine (5&#x02032;-dFUR) treatment, there was a strong synergistic cytotoxic activity, associated with altered target enzyme expression (<xref ref-type="other" rid="bib16">Magne <italic>et al</italic>, 2003</xref>). Clinical studies by Saltz and by Cunningham demonstrated the therapeutic role of an antibody directed to EGFR (<xref ref-type="other" rid="bib3">Cunningham <italic>et al</italic>, 2004</xref>; <xref ref-type="other" rid="bib27">Saltz <italic>et al</italic>, 2004</xref>).</p><p>We conducted a phase II study to determine the tolerability and response with gefitinib together with irinotecan, infusional 5-FU, and LV. The coadministration of these agents was associated with unexpectedly severe gastrointestinal toxicity and myelosuppression, and the RR in this small cohort was modest at best.</p><sec sec-type="methods"><title>PATIENTS AND METHODS</title><sec><title>Eligibility</title><p>Eligible patients were over 18 years with advanced or recurrent colorectal adenocarcinoma. No prior chemotherapy other than adjuvant 5-FU was allowed. Patients were required to have measurable disease. Eligibility criteria also included performance status 0&#x02013;2 (ECOG); adequate bone marrow (neutrophils &#x02a7e;1500&#x02009;mm<sup>&#x02212;3</sup>, platelets &#x02a7e;100&#x02009;000&#x02009;mm<sup>&#x02212;3</sup>), renal (creatinine &#x02a7d;1.5 times the upper limit of normal (ULN)), and hepatic (bilirubin &#x0003c;1.5 times ULN, and AST/ALT &#x02a7d;2 times ULN (&#x0003c;5 &#x000d7; ULN if liver metastasis) function. The study was approved by the University of Pennsylvania institutional review board. All patients signed written informed consent.</p></sec><sec><title>Pretreatment evaluation and follow-up</title><p>Pretreatment evaluation consisted of a history and physical examination, full blood count, electrolytes, creatinine, liver function tests and carcinoembryonic antigen (CEA), urinalysis, electrocardiogram, and baseline imaging. Clinical, haematologic, and biochemical evaluations were performed every 2 weeks. Toxicity was graded according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC).</p></sec><sec><title>Study design and treatment administration</title><p>This study was a nonrandomised safety and efficacy trial of 5-FU, LV, and irinotecan in combination with gefitinib in patients with advanced colorectal cancer. Patients received LV 400&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> as a 2&#x02009;h intravenous (i.v.) infusion, followed immediately by bolus 5-FU 400&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> and a 22&#x02009;h i.v. infusion of 5-FU 600&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>, on days 1 and 2, and irinotecan 180&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> as a 90&#x02009;min i.v. infusion during LV on day 1 only (5-FU400&#x02013;600/I180). Treatment was repeated every 2 weeks and one cycle consisted of 28 days. Gefitinib 250&#x02009;mg orally was administered continuously, beginning on day 1 (G250). Antiemetic prophylaxis with a 5-hydroxytryptamine-3-receptor antagonist and dexamethasone was used. Dose modifications were made for myelosuppression (5-FU and irinotecan), diarrhoea (5-FU, irinotecan, and gefitinib), mucositis (5-FU only), and skin rash (gefitinib only). The LV dose was not modified.</p></sec><sec><title>Response evaluation</title><p>Measurable lesions were reassessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) (<xref ref-type="other" rid="bib29">Therasse <italic>et al</italic>, 2000</xref>) after cycles 2 and 4, and then every three cycles until progression.</p></sec><sec><title>Statistical analysis</title><p>The purpose of this study was to assess the safety and efficacy of gefitinib, irinotecan, LV, and 5-FU in combination. We wished to be able to discern a toxicity rate of 29&#x00025; with the new regimen. With an accrual of 50 patients, we would have 80&#x00025; power to distinguish that level of toxicity from a 12&#x00025; rate observed in prior studies (<xref ref-type="other" rid="bib5">Douillard <italic>et al</italic>, 2000</xref>). We targeted an RR of 60&#x00025;, and planned to accrue 50 patients to give a 95&#x00025; confidence interval of 46&#x02013;72&#x00025;. All analyses were conducted using Stata 8.0, with two-sided tests of hypotheses and a <italic>P</italic>&#x0003c;0.05 criterion for statistical significance.</p></sec></sec><sec><title>RESULTS</title><sec><title>Patient characteristics</title><p>The demographic characteristics of the 13 patients are shown (<xref rid="tbl1" ref-type="table">Table 1</xref>). All were evaluable for toxicity and 12 for response. One patient was removed from study because of excessive first cycle toxicity.</p></sec><sec><title>Treatment administration</title><p>A total of 10 patients required dose reductions of irinotecan and 5-FU (<xref rid="tbl2" ref-type="table">Table 2</xref>). The first seven patients received I180/5-FU400&#x02013;600/G250. Four experienced grade 3 neutropenia and/or dehydration during the first cycle of therapy and required 20&#x00025; dose reduction of irinotecan and 5-FU (I150/5-FU320&#x02013;600/G250). Of these seven, four required an additional 20&#x00025; dose reduction (I120/5-FU200&#x02013;500/G250) because of dehydration or neutropenia. Because of this unacceptable level of toxicity, subsequent patients were treated at a reduced dose of irinotecan and 5-FU (I150/5-FU320&#x02013;600/G250). Of four patients treated at these doses, three developed grade 4 neutropenia after the first cycle and two grade 3 diarrhoea, requiring an additional 20&#x00025; dose reduction (I120/5-FU200&#x02013;500). For safety reasons, these doses were used in the subsequent patients. This dose level was well tolerated by eight patients in total (two new, six reduced) (<xref rid="tbl2" ref-type="table">Table 2</xref>). No dose changes were made for gefitinib.</p></sec><sec><title>Toxicity</title><p>The most frequent grade 3/4 adverse events during this study were gastrointestinal (mostly diarrhoea, 54&#x00025;) and haematologic (neutropenia, 62&#x00025;) (<xref rid="tbl3" ref-type="table">Table 3</xref>). Seven patients (54&#x00025;) developed grade 3 or 4 dehydration from diarrhoea, and all required hospitalisation. Two were removed from study because of toxicity.</p><p>Eight patients (62&#x00025;) developed grade 3 or 4 neutropenia, of whom three experienced neutropenic fever. One expired from sepsis after receiving one cycle of therapy. Of these eight patients, four had concomitant grade 3/4 diarrhoea.</p><p>Acneiform skin rash occurred in eight patients, and was mild and reversible. Grade 1/2 nausea and vomiting occurred in seven patients (54&#x00025;). Mucositis and fatigue were generally mild.</p></sec><sec><title>Response</title><p>The primary efficacy end point was RR. One patient achieved partial response (PR) for seven cycles (8&#x00025;, 95&#x00025; CI 0&#x02013;38&#x00025;). Seven of the 12 (58&#x00025;, 95&#x00025; CI 28&#x02013;85&#x00025;) evaluable patients had disease stabilisation that persisted for more than six cycles in six. Based on the excessive toxicity and low level of activity, after review of all results, the trial was closed.</p></sec></sec><sec><title>DISCUSSION</title><p>The combination of gefitinib with irinotecan, 5-FU, and LV demonstrated excessive gastrointestinal and haematologic toxicity in over half of the patients, despite the use of an infusional 5-FU schedule. The tolerable doses of irinotecan and 5-FU with gefitinib were one-third less than those commonly used. With these doses, activity appeared no better than expected, which prompted early closure of the study.</p><p>The excessive toxicity suggests an interaction between gefitinib and the chemotherapy. An interaction between gefitinib and 5-FU seems unlikely. Full doses of 5-FU/LV with gefitinib were tolerated on various schedules, without apparent pharmacokinetic interactions (<xref ref-type="other" rid="bib8">Hammond <italic>et al</italic>, 2001</xref>). Gefitinib 250&#x02009;mg can be administered with full doses of oxaliplatin/5-FU with tolerable toxicity, although a higher incidence of diarrhoea may suggest a possible pharmacodynamic interaction (<xref ref-type="other" rid="bib6">Fisher <italic>et al</italic>, 2004</xref>).</p><p>The profile of side effects in our study suggests an interaction with irinotecan rather than with 5-FU. Irinotecan is metabolised in the liver by several enzyme systems (<xref ref-type="other" rid="bib14">Kawato <italic>et al</italic>, 1991</xref>; <xref ref-type="other" rid="bib21">Rivory and Robert, 1995</xref>; <xref ref-type="other" rid="bib9">Haaz <italic>et al</italic>, 1997</xref>; <xref ref-type="other" rid="bib30">Xie <italic>et al</italic>, 2002</xref>). Cleavage by carboxylesterase yields the active metabolite SN-38, which is inactivated by glucuronide conjugation by uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) (<xref ref-type="other" rid="bib9">Haaz <italic>et al</italic>, 1997</xref>), variable activity of which is a determinant of toxicity (<xref ref-type="other" rid="bib12">Innocenti <italic>et al</italic>, 2004</xref>). Another pathway involves oxidation of the terminal piperidine ring by the P450 enzyme, CYP3A4 (<xref ref-type="other" rid="bib22">Rivory <italic>et al</italic>, 1996</xref>; <xref ref-type="other" rid="bib4">Dodds <italic>et al</italic>, 1998</xref>), of which gefitinib is a weak inhibitor. Additionally, mild elevations of bilirubin have been shown to predict neutropenia with weekly irinotecan, implicating hepatic excretion (<xref ref-type="other" rid="bib19">Meyerhardt <italic>et al</italic>, 2004</xref>).</p><p>Iacono <italic>et al</italic> reported a study of gefitinib and irinotecan in children. Concomitant administration of gefitinib reduced irinotecan clearance and increased the AUC of SN-38 (<xref ref-type="other" rid="bib11">Iacono <italic>et al</italic>, 2004</xref>). In another phase I clinical trial (<xref ref-type="other" rid="bib2">Chau <italic>et al</italic>, 2004</xref>) of gefitinib with irinotecan, dose reduction was required. We propose that the interaction of irinotecan and gefitinib in our trial is likely to have been pharmacokinetic, resulting in greater than anticipated exposure to irinotecan and its active metabolite. Interestingly, <xref ref-type="other" rid="bib18">Messersmith <italic>et al</italic> (2004)</xref> have recently reported excessive toxicity requiring early closure of the study in a phase I trial of a combination of erlotinib with reduced doses of irinotecan and infusional 5-FU. A pharmacokinetic interaction between irinotecan, 5-FU, and erlotinib could not explain the toxicity. Additionally, blockage of the EGFR may not account for this level of toxicity since combination of Erbitux with irinotecan has not resulted in such severe toxicity (<xref ref-type="other" rid="bib3">Cunningham <italic>et al</italic>, 2004</xref>). An interaction between gefitinib and the multidrug resistance ABC transporter could have contributed to toxicity. Gefitinib inhibits ABCG2-dependent active drug extrusion, which mediates irinotecan efflux and protects cells from irinotecan toxicity (<xref ref-type="other" rid="bib31">Wierdl <italic>et al</italic>, 2003</xref>; <xref ref-type="other" rid="bib20">Ozvegy-Laczka <italic>et al</italic>, 2004</xref>).</p><p>While both of these possibilities need consideration in using these drugs in combination, the implied increase in sources of intrapatient variability was perceived as a safety hazard for further development on a solely empirical basis.</p></sec></body><back><ref-list><ref id="bib1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bajetta</surname><given-names>E</given-names></name><name><surname>Di Bartolomeo</surname><given-names>M</given-names></name><name><surname>Mariani</surname><given-names>L</given-names></name><name><surname>Cassata</surname><given-names>A</given-names></name><name><surname>Artale</surname><given-names>S</given-names></name><name><surname>Frustaci</surname><given-names>S</given-names></name><name><surname>Pinotti</surname><given-names>G</given-names></name><name><surname>Bonetti</surname><given-names>A</given-names></name><name><surname>Carreca</surname><given-names>I</given-names></name><name><surname>Biasco</surname><given-names>G</given-names></name><name><surname>Bonaglia</surname><given-names>L</given-names></name><name><surname>Marini</surname><given-names>G</given-names></name><name><surname>Iannelli</surname><given-names>A</given-names></name><name><surname>Cortinovis</surname><given-names>D</given-names></name><name><surname>Ferrario</surname><given-names>E</given-names></name><name><surname>Beretta</surname><given-names>E</given-names></name><name><surname>Lambiase</surname><given-names>A</given-names></name><name><surname>Buzzoni</surname><given-names>R</given-names></name></person-group><article-title>Randomized multicenter phase II trial of two different schedule of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma</article-title><source>Cancer</source><year>2004</year><volume>100</volume><fpage>279</fpage><lpage>287</lpage><!--PubMed citation query: 'Cancer||100|279||bib1|'--><pub-id pub-id-type="pmid">14716761</pub-id></citation></ref><ref id="bib2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chau</surname><given-names>I</given-names></name><name><surname>Massey</surname><given-names>A</given-names></name><name><surname>iggins</surname><given-names>L</given-names></name><name><surname>Botwood</surname><given-names>N</given-names></name><name><surname>Cunningham</surname><given-names>D</given-names></name></person-group><article-title>Phase I study of gefitinib in combination with irinotecan in patients with fluoropyrimidine refractory advanced colorectal cancer</article-title><source>Proc Am Soc Clin Oncol</source><year>2004</year><volume>23</volume><fpage>3572a</fpage><!--PubMed citation query: 'Proc Am Soc Clin Oncol||23|3572a||bib2|'--></citation></ref><ref id="bib3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cunningham</surname><given-names>D</given-names></name><name><surname>Humblet</surname><given-names>Y</given-names></name><name><surname>Siena</surname><given-names>S</given-names></name><name><surname>Khayat</surname><given-names>D</given-names></name><name><surname>Bleiberg</surname><given-names>H</given-names></name><name><surname>Santoro</surname><given-names>A</given-names></name><name><surname>Bets</surname><given-names>D</given-names></name><name><surname>Mueser</surname><given-names>M</given-names></name><name><surname>Harstrick</surname><given-names>A</given-names></name><name><surname>Verslype</surname><given-names>C</given-names></name><name><surname>Chau</surname><given-names>I</given-names></name><name><surname>Van Cutsem</surname><given-names>E</given-names></name></person-group><article-title>Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer</article-title><source>N Engl J Med</source><year>2004</year><volume>351</volume><fpage>337</fpage><lpage>345</lpage><!--PubMed citation query: 'N Engl J Med||351|337||bib3|'--><pub-id pub-id-type="pmid">15269313</pub-id></citation></ref><ref id="bib4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dodds</surname><given-names>HM</given-names></name><name><surname>Haaz</surname><given-names>MC</given-names></name><name><surname>Riou</surname><given-names>JF</given-names></name><name><surname>Robert</surname><given-names>J</given-names></name><name><surname>Rivory</surname><given-names>LP</given-names></name></person-group><article-title>Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38</article-title><source>J Pharmacol Exp Ther</source><year>1998</year><volume>286</volume><fpage>578</fpage><lpage>583</lpage><!--PubMed citation query: 'J Pharmacol Exp Ther||286|578||bib4|'--><pub-id pub-id-type="pmid">9655905</pub-id></citation></ref><ref id="bib5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Douillard</surname><given-names>JY</given-names></name><name><surname>Cunningham</surname><given-names>D</given-names></name><name><surname>Roth</surname><given-names>AD</given-names></name><name><surname>Navarro</surname><given-names>M</given-names></name><name><surname>James</surname><given-names>RD</given-names></name><name><surname>Karasek</surname><given-names>P</given-names></name><name><surname>Jandik</surname><given-names>P</given-names></name><name><surname>Iveson</surname><given-names>T</given-names></name><name><surname>Carmichael</surname><given-names>J</given-names></name><name><surname>Alakl</surname><given-names>M</given-names></name><name><surname>Gruia</surname><given-names>G</given-names></name><name><surname>Awad</surname><given-names>L</given-names></name><name><surname>Rougier</surname><given-names>P</given-names></name></person-group><article-title>Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer; a multicenter randomized trial</article-title><source>Lancet</source><year>2000</year><volume>355</volume><fpage>1041</fpage><lpage>1047</lpage><!--PubMed citation query: 'Lancet||355|1041||bib5|'--><pub-id pub-id-type="pmid">10744089</pub-id></citation></ref><ref id="bib6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>GA</given-names></name><name><surname>Kuo</surname><given-names>T</given-names></name><name><surname>Cho</surname><given-names>CD</given-names></name><name><surname>Halsey</surname><given-names>J</given-names></name><name><surname>Jambalos</surname><given-names>CN</given-names></name><name><surname>Schwartz</surname><given-names>EJ</given-names></name><name><surname>Robert</surname><given-names>RV</given-names></name><name><surname>Advani</surname><given-names>RH</given-names></name><name><surname>Wakalee</surname><given-names>HA</given-names></name></person-group><article-title>A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer</article-title><source>Proc Am Soc Clin Oncol</source><year>2004</year><volume>22</volume><fpage>3514a</fpage><!--PubMed citation query: 'Proc Am Soc Clin Oncol||22|3514a||bib6|'--></citation></ref><ref id="bib7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fusch</surname><given-names>CS</given-names></name><name><surname>Moore</surname><given-names>MR</given-names></name><name><surname>Harker</surname><given-names>G</given-names></name><name><surname>Villa</surname><given-names>L</given-names></name><name><surname>Rinaldi</surname><given-names>D</given-names></name><name><surname>Hecht</surname><given-names>JR</given-names></name></person-group><article-title>Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer</article-title><source>J Clin Oncol</source><year>2003</year><volume>21</volume><fpage>807</fpage><lpage>814</lpage><!--PubMed citation query: 'J Clin Oncol||21|807||bib7|'--><pub-id pub-id-type="pmid">12610178</pub-id></citation></ref><ref id="bib8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hammond</surname><given-names>LA</given-names></name><name><surname>Figueroa</surname><given-names>J</given-names></name><name><surname>Schwartzberg</surname><given-names>L</given-names></name><name><surname>Ochoa</surname><given-names>L</given-names></name><name><surname>Hidalgo</surname><given-names>M</given-names></name><name><surname>Olivo</surname><given-names>N</given-names></name><name><surname>Schwartz</surname><given-names>G</given-names></name><name><surname>Smith</surname><given-names>L</given-names></name><name><surname>Ochs</surname><given-names>J</given-names></name><name><surname>Rowinsky</surname><given-names>EK</given-names></name></person-group><article-title>Feasibility and pharmacokinetic trial of ZD1839 (Iressa&#x02122;), an epidermal growth factor receptor tyrosine kinase inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced colorectal cancer</article-title><source>Proc Am Soc Clin Oncol</source><year>2001</year><volume>20</volume><fpage>544a</fpage><!--PubMed citation query: 'Proc Am Soc Clin Oncol||20|544a||bib8|'--></citation></ref><ref id="bib9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haaz</surname><given-names>MC</given-names></name><name><surname>Rivory</surname><given-names>L</given-names></name><name><surname>Jantet</surname><given-names>S</given-names></name><name><surname>Ratanasavanh</surname><given-names>D</given-names></name><name><surname>Robert</surname><given-names>J</given-names></name></person-group><article-title>Glucuronidation of SN-38, the active metabolite of irinotecan, by human hepatic microsomes</article-title><source>Pharmacol Toxicol</source><year>1997</year><volume>80</volume><fpage>91</fpage><lpage>96</lpage><!--PubMed citation query: 'Pharmacol Toxicol||80|91||bib9|'--><pub-id pub-id-type="pmid">9060040</pub-id></citation></ref><ref id="bib10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>JY</given-names></name><name><surname>Lee</surname><given-names>DH</given-names></name><name><surname>Kim</surname><given-names>HY</given-names></name><name><surname>Kim</surname><given-names>EA</given-names></name><name><surname>Lee</surname><given-names>JJ</given-names></name><name><surname>Ju</surname><given-names>SY</given-names></name><name><surname>Shin</surname><given-names>EH</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name></person-group><article-title>A phase II study of weekly irinotecan and capecitabine in patients with previously treated non-small cell lung cancer</article-title><source>Clin Cancer Res</source><year>2003</year><volume>9</volume><fpage>5509</fpage><lpage>5514</lpage><!--PubMed citation query: 'Clin Cancer Res||9|5509||bib10|'--></citation></ref><ref id="bib11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iacono</surname><given-names>LC</given-names></name><name><surname>Furman</surname><given-names>WL</given-names></name><name><surname>Crews</surname><given-names>KR</given-names></name><name><surname>Panetta</surname><given-names>JC</given-names></name><name><surname>Freeman</surname><given-names>BB</given-names></name><name><surname>Daw</surname><given-names>NC</given-names></name><name><surname>Stewart</surname><given-names>CF</given-names></name></person-group><article-title>Effect of gefitinib on the systemic disposition of intravenous irinotecan in pediatric patients with refractory solid tumors</article-title><source>Proc Am Soc Clin Oncol</source><year>2004</year><volume>23</volume><fpage>2011a</fpage><!--PubMed citation query: 'Proc Am Soc Clin Oncol||23|2011a||bib11|'--></citation></ref><ref id="bib12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Innocenti</surname><given-names>F</given-names></name><name><surname>Undevia</surname><given-names>SD</given-names></name><name><surname>Iyer</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>PX</given-names></name><name><surname>Das</surname><given-names>S</given-names></name><name><surname>Kocherginsky</surname><given-names>M</given-names></name><name><surname>Karrison</surname><given-names>T</given-names></name><name><surname>Janisch</surname><given-names>L</given-names></name><name><surname>Ramirez</surname><given-names>J</given-names></name><name><surname>Rudin</surname><given-names>CM</given-names></name><name><surname>Vokes</surname><given-names>EE</given-names></name><name><surname>Ratain</surname><given-names>MJ</given-names></name></person-group><article-title>Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><fpage>1382</fpage><lpage>1388</lpage><!--PubMed citation query: 'J Clin Oncol||22|1382||bib12|'--><pub-id pub-id-type="pmid">15007088</pub-id></citation></ref><ref id="bib13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jordan</surname><given-names>K</given-names></name><name><surname>Kellner</surname><given-names>O</given-names></name><name><surname>Kegel</surname><given-names>T</given-names></name><name><surname>Schmoll</surname><given-names>HJ</given-names></name><name><surname>Grothey</surname><given-names>A</given-names></name></person-group><article-title>Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers</article-title><source>Clin Colorectal Cancer</source><year>2004</year><volume>4</volume><fpage>46</fpage><lpage>50</lpage><!--PubMed citation query: 'Clin Colorectal Cancer||4|46||bib13|'--><pub-id pub-id-type="pmid">15207020</pub-id></citation></ref><ref id="bib14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kawato</surname><given-names>Y</given-names></name><name><surname>Aonuma</surname><given-names>M</given-names></name><name><surname>Hirota</surname><given-names>Y</given-names></name><name><surname>Kuga</surname><given-names>H</given-names></name><name><surname>Sato</surname><given-names>K</given-names></name></person-group><article-title>Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11</article-title><source>Cancer Res</source><year>1991</year><volume>51</volume><fpage>4187</fpage><lpage>4191</lpage><!--PubMed citation query: 'Cancer Res||51|4187||bib14|'--><pub-id pub-id-type="pmid">1651156</pub-id></citation></ref><ref id="bib15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koizumi</surname><given-names>F</given-names></name><name><surname>Kanzawa</surname><given-names>F</given-names></name><name><surname>Ueda</surname><given-names>Y</given-names></name><name><surname>Koh</surname><given-names>Y</given-names></name><name><surname>Tsukiyama</surname><given-names>S</given-names></name><name><surname>Taguchi</surname><given-names>F</given-names></name><name><surname>Tamura</surname><given-names>T</given-names></name><name><surname>Saijo</surname><given-names>N</given-names></name><name><surname>Nishio</surname><given-names>K</given-names></name></person-group><article-title>Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib (&#x02018;Iressa') and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells</article-title><source>Int J Cancer</source><year>2004</year><volume>108</volume><fpage>464</fpage><lpage>472</lpage><!--PubMed citation query: 'Int J Cancer||108|464||bib15|'--><pub-id pub-id-type="pmid">14648715</pub-id></citation></ref><ref id="bib16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Magne</surname><given-names>N</given-names></name><name><surname>Fischel</surname><given-names>JL</given-names></name><name><surname>Dubreuil</surname><given-names>A</given-names></name><name><surname>Formento</surname><given-names>P</given-names></name><name><surname>Ciccolini</surname><given-names>J</given-names></name><name><surname>Formento</surname><given-names>JL</given-names></name><name><surname>Tiffon</surname><given-names>C</given-names></name><name><surname>Renee</surname><given-names>N</given-names></name><name><surname>Marchetti</surname><given-names>S</given-names></name><name><surname>Etienne</surname><given-names>MC</given-names></name><name><surname>Milano</surname><given-names>G</given-names></name></person-group><article-title>ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine</article-title><source>Clin Cancer Res</source><year>2003</year><volume>9</volume><fpage>4735</fpage><lpage>4742</lpage><!--PubMed citation query: 'Clin Cancer Res||9|4735||bib16|'--><pub-id pub-id-type="pmid">14581344</pub-id></citation></ref><ref id="bib17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mayer</surname><given-names>A</given-names></name><name><surname>Takimoto</surname><given-names>M</given-names></name><name><surname>Fritz</surname><given-names>E</given-names></name><name><surname>Schellander</surname><given-names>G</given-names></name><name><surname>Kofler</surname><given-names>K</given-names></name><name><surname>Ludwig</surname><given-names>H</given-names></name></person-group><article-title>The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer</article-title><source>Cancer</source><year>1993</year><volume>71</volume><fpage>2454</fpage><lpage>2460</lpage><!--PubMed citation query: 'Cancer||71|2454||bib17|'--><pub-id pub-id-type="pmid">8095852</pub-id></citation></ref><ref id="bib18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Messersmith</surname><given-names>WA</given-names></name><name><surname>Laheru</surname><given-names>DA</given-names></name><name><surname>Senzer</surname><given-names>NN</given-names></name><name><surname>Donehower</surname><given-names>RC</given-names></name><name><surname>Grouleff</surname><given-names>P</given-names></name><name><surname>Rogers</surname><given-names>T</given-names></name><name><surname>Kelley</surname><given-names>SK</given-names></name><name><surname>Ramies</surname><given-names>DA</given-names></name><name><surname>Lum</surname><given-names>BL</given-names></name><name><surname>Hidalgo</surname><given-names>M</given-names></name></person-group><article-title>Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicity</article-title><source>Clin Cancer Res</source><year>2004</year><volume>10</volume><fpage>6522</fpage><lpage>6527</lpage><!--PubMed citation query: 'Clin Cancer Res||10|6522||bib18|'--><pub-id pub-id-type="pmid">15475439</pub-id></citation></ref><ref id="bib19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meyerhardt</surname><given-names>JA</given-names></name><name><surname>Kwok</surname><given-names>A</given-names></name><name><surname>Ratain</surname><given-names>MJ</given-names></name><name><surname>McGovren</surname><given-names>JP</given-names></name><name><surname>Fuchs</surname><given-names>CS</given-names></name></person-group><article-title>Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><fpage>1439</fpage><lpage>1446</lpage><!--PubMed citation query: 'J Clin Oncol||22|1439||bib19|'--><pub-id pub-id-type="pmid">15084617</pub-id></citation></ref><ref id="bib20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ozvegy-Laczka</surname><given-names>C</given-names></name><name><surname>Hegedus</surname><given-names>T</given-names></name><name><surname>Varady</surname><given-names>G</given-names></name><name><surname>Ujhelly</surname><given-names>O</given-names></name><name><surname>Schuetz</surname><given-names>JD</given-names></name><name><surname>Varadi</surname><given-names>A</given-names></name><name><surname>Keri</surname><given-names>G</given-names></name><name><surname>Orfi</surname><given-names>L</given-names></name><name><surname>Nemet</surname><given-names>K</given-names></name><name><surname>Sarkadi</surname><given-names>B</given-names></name></person-group><article-title>High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter</article-title><source>Mol Pharmacol</source><year>2004</year><volume>65</volume><fpage>1485</fpage><lpage>1495</lpage><!--PubMed citation query: 'Mol Pharmacol||65|1485||bib20|'--><pub-id pub-id-type="pmid">15155841</pub-id></citation></ref><ref id="bib21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rivory</surname><given-names>LP</given-names></name><name><surname>Robert</surname><given-names>J</given-names></name></person-group><article-title>Identification and kinetics of a beta-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan</article-title><source>Cancer Chemother Pharmacol</source><year>1995</year><volume>36</volume><fpage>176</fpage><lpage>179</lpage><!--PubMed citation query: 'Cancer Chemother Pharmacol||36|176||bib21|'--><pub-id pub-id-type="pmid">7767955</pub-id></citation></ref><ref id="bib22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rivory</surname><given-names>LP</given-names></name><name><surname>Riou</surname><given-names>JF</given-names></name><name><surname>Haaz</surname><given-names>MC</given-names></name><name><surname>Sable</surname><given-names>S</given-names></name><name><surname>Vuilhorgne</surname><given-names>M</given-names></name><name><surname>Commercon</surname><given-names>A</given-names></name><name><surname>Pond</surname><given-names>SM</given-names></name><name><surname>Robert</surname><given-names>J</given-names></name></person-group><article-title>Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients</article-title><source>Cancer Res</source><year>1996</year><volume>56</volume><fpage>3689</fpage><lpage>3694</lpage><!--PubMed citation query: 'Cancer Res||56|3689||bib22|'--><pub-id pub-id-type="pmid">8706009</pub-id></citation></ref><ref id="bib23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rothenberg</surname><given-names>ML</given-names></name><name><surname>Meropol</surname><given-names>NJ</given-names></name><name><surname>Poplin</surname><given-names>EA</given-names></name><name><surname>Van Cutsem</surname><given-names>E</given-names></name><name><surname>Wadler</surname><given-names>S</given-names></name></person-group><article-title>Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel</article-title><source>J Clin Oncol</source><year>2001</year><volume>19</volume><fpage>3801</fpage><lpage>3807</lpage><!--PubMed citation query: 'J Clin Oncol||19|3801||bib23|'--><pub-id pub-id-type="pmid">11559717</pub-id></citation></ref><ref id="bib24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rougier</surname><given-names>P</given-names></name><name><surname>Bugat</surname><given-names>R</given-names></name><name><surname>Douillard</surname><given-names>JY</given-names></name><name><surname>Culine</surname><given-names>S</given-names></name><name><surname>Suc</surname><given-names>E</given-names></name><name><surname>Brunet</surname><given-names>P</given-names></name><name><surname>Becouarn</surname><given-names>Y</given-names></name><name><surname>Ychou</surname><given-names>M</given-names></name><name><surname>Marty</surname><given-names>M</given-names></name><name><surname>Extra</surname><given-names>JM</given-names></name><name><surname>Bonneterre</surname><given-names>J</given-names></name><name><surname>Adenis</surname><given-names>A</given-names></name><name><surname>Seitz</surname><given-names>JF</given-names></name><name><surname>Ganem</surname><given-names>G</given-names></name><name><surname>Namer</surname><given-names>M</given-names></name><name><surname>Conroy</surname><given-names>T</given-names></name><name><surname>Negrier</surname><given-names>S</given-names></name><name><surname>Merrouche</surname><given-names>Y</given-names></name><name><surname>Burki</surname><given-names>F</given-names></name><name><surname>Mousseau</surname><given-names>M</given-names></name><name><surname>Herait</surname><given-names>P</given-names></name><name><surname>Mahjoubi</surname><given-names>M</given-names></name></person-group><article-title>Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy</article-title><source>J Clin Oncol</source><year>1997</year><volume>15</volume><fpage>251</fpage><lpage>260</lpage><!--PubMed citation query: 'J Clin Oncol||15|251||bib24|'--><pub-id pub-id-type="pmid">8996150</pub-id></citation></ref><ref id="bib25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saloman</surname><given-names>DS</given-names></name><name><surname>Brandt</surname><given-names>R</given-names></name><name><surname>Fortunato</surname><given-names>C</given-names></name><name><surname>Normanno</surname><given-names>N</given-names></name></person-group><article-title>Epidermal growth factor-related peptides and their receptors in human malignancies</article-title><source>Crit Rev Oncol/Hematol</source><year>1995</year><volume>19</volume><fpage>183</fpage><lpage>232</lpage><!--PubMed citation query: 'Crit Rev Oncol/Hematol||19|183||bib25|'--></citation></ref><ref id="bib26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saltz</surname><given-names>LB</given-names></name><name><surname>Cox</surname><given-names>JV</given-names></name><name><surname>Blanke</surname><given-names>C</given-names></name><name><surname>Rosen</surname><given-names>LS</given-names></name><name><surname>Fehrenbacher</surname><given-names>L</given-names></name><name><surname>Moore</surname><given-names>MJ</given-names></name><name><surname>Maroun</surname><given-names>JA</given-names></name><name><surname>Ackland</surname><given-names>SP</given-names></name><name><surname>Locker</surname><given-names>PK</given-names></name><name><surname>Pirotta</surname><given-names>N</given-names></name><name><surname>Elfring</surname><given-names>GL</given-names></name><name><surname>Miller</surname><given-names>LL</given-names></name></person-group><article-title>Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer</article-title><source>N Engl J Med</source><year>2000</year><volume>343</volume><fpage>905</fpage><lpage>914</lpage><!--PubMed citation query: 'N Engl J Med||343|905||bib26|'--><pub-id pub-id-type="pmid">11006366</pub-id></citation></ref><ref id="bib27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saltz</surname><given-names>LB</given-names></name><name><surname>Meropol</surname><given-names>NJ</given-names></name><name><surname>Loehrer</surname><given-names>PJ</given-names></name><name><surname>Needle</surname><given-names>MN</given-names></name><name><surname>Kopit</surname><given-names>J</given-names></name><name><surname>Mayer</surname><given-names>RJ</given-names></name></person-group><article-title>Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><fpage>1201</fpage><lpage>1208</lpage><!--PubMed citation query: 'J Clin Oncol||22|1201||bib27|'--><pub-id pub-id-type="pmid">14993230</pub-id></citation></ref><ref id="bib28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tewes</surname><given-names>M</given-names></name><name><surname>Schleucher</surname><given-names>N</given-names></name><name><surname>Achterrath</surname><given-names>W</given-names></name><name><surname>Wilke</surname><given-names>HJ</given-names></name><name><surname>Frings</surname><given-names>S</given-names></name><name><surname>Seeber</surname><given-names>S</given-names></name><name><surname>Harstrick</surname><given-names>A</given-names></name><name><surname>Rustum</surname><given-names>YM</given-names></name><name><surname>Vanhoefer</surname><given-names>U</given-names></name></person-group><article-title>Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study</article-title><source>Ann Oncol</source><year>2003</year><volume>14</volume><fpage>1442</fpage><lpage>1448</lpage><!--PubMed citation query: 'Ann Oncol||14|1442||bib28|'--><pub-id pub-id-type="pmid">12954586</pub-id></citation></ref><ref id="bib29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Therasse</surname><given-names>P</given-names></name><name><surname>Arbuck</surname><given-names>SG</given-names></name><name><surname>Eisenhauer</surname><given-names>EA</given-names></name><name><surname>Wanders</surname><given-names>J</given-names></name><name><surname>Kaplan</surname><given-names>RS</given-names></name><name><surname>Rubinstein</surname><given-names>L</given-names></name><name><surname>Verweij</surname><given-names>J</given-names></name><name><surname>Van Glabbeke</surname><given-names>M</given-names></name><name><surname>van Oosterom</surname><given-names>AT</given-names></name><name><surname>Christian</surname><given-names>MC</given-names></name><name><surname>Gwyther</surname><given-names>SG</given-names></name></person-group><article-title>New guidelines to evaluate the response to treatment in solid tumors</article-title><source>J Natl Cancer Inst</source><year>2000</year><volume>92</volume><fpage>205</fpage><lpage>216</lpage><!--PubMed citation query: 'J Natl Cancer Inst||92|205||bib29|'--><pub-id pub-id-type="pmid">10655437</pub-id></citation></ref><ref id="bib30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>R</given-names></name><name><surname>Mathijssen</surname><given-names>RHJ</given-names></name><name><surname>Sparreboom</surname><given-names>A</given-names></name><name><surname>Verweij</surname><given-names>J</given-names></name><name><surname>Karlsson</surname><given-names>MO</given-names></name></person-group><article-title>Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis</article-title><source>J Clin Oncol</source><year>2002</year><volume>20</volume><fpage>3293</fpage><lpage>3301</lpage><!--PubMed citation query: 'J Clin Oncol||20|3293||bib30|'--><pub-id pub-id-type="pmid">12149304</pub-id></citation></ref><ref id="bib31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wierdl</surname><given-names>M</given-names></name><name><surname>Wall</surname><given-names>A</given-names></name><name><surname>Morton</surname><given-names>CL</given-names></name><name><surname>Sampath</surname><given-names>J</given-names></name><name><surname>Danks</surname><given-names>MK</given-names></name><name><surname>Schuetz</surname><given-names>JD</given-names></name><name><surname>Potter</surname><given-names>PM</given-names></name></person-group><article-title>Carboxylesterase-mediated sensitization of human tumor cells to CPT-11 cannot override ABCG2-mediated drug resistance</article-title><source>Mol Pharmacol</source><year>2003</year><volume>64</volume><fpage>279</fpage><lpage>288</lpage><!--PubMed citation query: 'Mol Pharmacol||64|279||bib31|'--><pub-id pub-id-type="pmid">12869632</pub-id></citation></ref></ref-list></back><floats-wrap><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p content-type="table-title">Patient characteristics</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="right"/></colgroup><tbody valign="top"><tr><td align="left" valign="top" charoff="50">No. of patients</td><td align="right" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Entered</td><td align="right" valign="top" charoff="50">13</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Assessable</td><td align="right" valign="top" charoff="50">12</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="right" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Sex</td><td align="right" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Male</td><td align="right" valign="top" charoff="50">6</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Female</td><td align="right" valign="top" charoff="50">7</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="right" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Age (years)</td><td align="right" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Range</td><td align="right" valign="top" charoff="50">49&#x02013;72</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Median</td><td align="right" valign="top" charoff="50">58</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="right" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">ECOG performance status</td><td align="right" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;1</td><td align="right" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;1</td><td align="right" valign="top" charoff="50">2</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;2</td><td align="right" valign="top" charoff="50">1</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="right" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Site of tumour</td><td align="right" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Colon</td><td align="right" valign="top" charoff="50">12</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Rectum</td><td align="right" valign="top" charoff="50">1</td></tr><tr><td align="left" valign="top" charoff="50">Liver involvement</td><td align="right" valign="top" charoff="50">10</td></tr></tbody></table></table-wrap><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><p content-type="table-title">Toxicity related to the combination of irinotecan/5-FU/gefitinib by dose</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th colspan="2" align="center" valign="top" charoff="50"><bold><italic>N</italic></bold><hr/></th><th colspan="8" align="center" valign="top" charoff="50"><bold>Maximum toxicity/grade</bold><hr/></th></tr><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" charoff="50"><bold>New<sup>a</sup></bold><hr/></th><th align="center" valign="top" charoff="50"><bold>Total<sup>b</sup></bold><hr/></th><th colspan="4" align="center" valign="top" charoff="50"><bold>Nonhaematologic</bold><hr/></th><th colspan="4" align="center" valign="top" charoff="50"><bold>Haematologic</bold><hr/></th></tr><tr><th align="left" valign="top" charoff="50"><bold>Dose</bold></th><th align="center" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" charoff="50"><bold>G 1</bold></th><th align="center" valign="top" charoff="50"><bold>G 2</bold></th><th align="center" valign="top" charoff="50"><bold>G 3</bold></th><th align="center" valign="top" charoff="50"><bold>G 4</bold></th><th align="center" valign="top" charoff="50"><bold>G 1</bold></th><th align="center" valign="top" charoff="50"><bold>G 2</bold></th><th align="center" valign="top" charoff="50"><bold>G 3</bold></th><th align="center" valign="top" charoff="50"><bold>G 4</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">I180/5-FU400&#x02013;600</td><td align="center" valign="top" charoff="50">7</td><td align="center" valign="top" charoff="50">7</td><td align="center" valign="top" charoff="50">7</td><td align="center" valign="top" charoff="50">7</td><td align="center" valign="top" charoff="50">4</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">2</td><td align="center" valign="top" charoff="50">4</td><td align="center" valign="top" charoff="50">3</td><td align="center" valign="top" charoff="50">2</td></tr><tr><td align="left" valign="top" charoff="50">I150/5-FU320&#x02013;500</td><td align="center" valign="top" charoff="50">4</td><td align="center" valign="top" charoff="50">7</td><td align="center" valign="top" charoff="50">4</td><td align="center" valign="top" charoff="50">4</td><td align="center" valign="top" charoff="50">3</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">2</td></tr><tr><td align="left" valign="top" charoff="50">I120/5-FU200&#x02013;500</td><td align="center" valign="top" charoff="50">2</td><td align="center" valign="top" charoff="50">8</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">2</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr></tbody></table><table-wrap-foot><fn id="tbfnote1"><label/><p>Gefitinib dose was 250&#x02009;mg daily and it was not reduced. 5-FU=5-fluorouracil.</p></fn><fn id="tbfnote2"><label>a</label><p>Number of patients who received the given irinotecan and 5-FU doses on cycle 1.</p></fn><fn id="tbfnote3"><label>b</label><p>Number of patients who received the given irinotecan and 5-FU doses on cycle 1 plus as reductions in subsequent cycles.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl3" position="float"><label>Table 3</label><caption><p content-type="table-title">Toxicity related to the combination of irinotecan/FU/LV/gefitinib by cycle</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Toxicity</bold></th><th align="center" valign="top" charoff="50"><bold>Cycle 1 (<italic>N</italic>=13)</bold></th><th align="center" valign="top" charoff="50"><bold>Cycle 2 (<italic>N</italic>=10)</bold></th><th align="center" valign="top" charoff="50"><bold>Cycle 3 (<italic>N</italic>=7)</bold></th><th align="center" valign="top" charoff="50"><bold>Cycle 4 (<italic>N</italic>=7)</bold></th><th align="center" valign="top" charoff="50"><bold>Cycle 5 (<italic>N</italic>=6)</bold></th><th align="center" valign="top" charoff="50"><bold>Cycle 6 (<italic>N</italic>=4)</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Diarrhoea</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Grade 1 or 2</td><td align="center" valign="top" charoff="50">5</td><td align="center" valign="top" charoff="50">3</td><td align="center" valign="top" charoff="50">2</td><td align="center" valign="top" charoff="50">2</td><td align="center" valign="top" charoff="50">3</td><td align="center" valign="top" charoff="50">2</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Grade 3 or 4</td><td align="center" valign="top" charoff="50">2</td><td align="center" valign="top" charoff="50">2</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">2</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">1</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Nausea/vomiting</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Grade 1 or 2</td><td align="center" valign="top" charoff="50">7</td><td align="center" valign="top" charoff="50">5</td><td align="center" valign="top" charoff="50">4</td><td align="center" valign="top" charoff="50">2</td><td align="center" valign="top" charoff="50">2</td><td align="center" valign="top" charoff="50">3</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Grade 3 or 4</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Dehydration</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Grade 1 or 2</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Grade 3 or 4</td><td align="center" valign="top" charoff="50">3</td><td align="center" valign="top" charoff="50">3</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Mucositis</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Grade 1 or 2</td><td align="center" valign="top" charoff="50">2</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Grade 3 or 4</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Fatigue</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Grade 1 or 2</td><td align="center" valign="top" charoff="50">6</td><td align="center" valign="top" charoff="50">5</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">2</td><td align="center" valign="top" charoff="50">2</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Grade 3 or 4</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Skin rash</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Grade 1 or 2</td><td align="center" valign="top" charoff="50">6</td><td align="center" valign="top" charoff="50">3</td><td align="center" valign="top" charoff="50">3</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">1</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Grade 3 or 4</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Neutropenia</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Grade 1 or 2</td><td align="center" valign="top" charoff="50">2</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Grade 3 or 4</td><td align="center" valign="top" charoff="50">5</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">2</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Neutropenic fever</td><td align="center" valign="top" charoff="50">2</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Anaemia</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Grade 1 or 2</td><td align="center" valign="top" charoff="50">5</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Grade 3 or 4</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="tbfnote4"><label/><p>5-FU=5-fluorouracil; LV=leucovorin.</p></fn></table-wrap-foot></table-wrap></floats-wrap></article>


